Espinoza Octavio

CFO Espinoza sells 3,057 shares of LGND at $225.00 for $687,825; reduces stake by -12.7% to 21,010 shares

Espinoza, the CFO of Ligand Pharmaceuticals, sold 3,057 shares at $225.00 on 2026-03-11 for a total value of $687,825.00, reducing his holdings from 24,067 to 21,010 shares. The transaction occurred at a price 11.1% above the current price of $202.91, and notably, this sale follows an unusually active period with 5 separate sales executed on 2026-03-04 (outcomes not yet measurable at 90 days). His cross-ticker historical track record shows 16 prior sells with a 20.00% well-timed rate and an average 90-day return of +12.7% after sells—indicating his prior sells have not typically preceded declines. The company reports strong fundamentals with annual revenue growth of +60.4%, net income of $117,273,000.00 exceeding quarterly revenue of $115,461,000.00, and a P/E of 22.85. The concentrated selling pattern (multiple sales within a week) warrants observation to determine whether this reflects a sustained directional view or tactical rebalancing.

CFO Octavio Espinoza sells 13,423 shares of LGND for $2.8M in 11 transactions on 2026-03-04

Chief Financial Officer Octavio Espinoza executed 11 separate sales totaling 13,423 shares for $2,762,822.25 on 2026-03-04, reducing his holdings by 38.3% from 35,085 to 21,662 shares. The transactions were executed at prices ranging from $198.71 to $208.80, with a blended average of $205.83, compared to the current price of $201.90. His prior trading history at LGND shows mixed timing: his two 2025 buys generated strong 90-day returns (+40.8% and +40.2%), while his three prior sells at this ticker produced a negative 90-day return of -11.6% in one instance and positive returns of +19.0% in two others. Given LGND's current valuation metrics (P/E of 22.74, recent 60.4% annual revenue growth, and net income of $117.3M on quarterly revenue of $115.5M), the sale represents a significant position reduction by a senior executive with mixed timing results on prior transactions at this ticker.

CFO Espinoza purchased 1,500 shares at blended avg $104.06 (2 transactions totaling $156,090.00) on 2025-05-09

Octavio Espinoza, Chief Financial Officer of Ligand Pharmaceuticals, executed 2 separate purchases totaling 1,500 shares for $156,090.00, increasing his holdings from 26,432 to 27,932 shares (+5.7%). The purchase prices ($103.89 and $104.40) sit within the 52-week range ($77.82–$129.90) and slightly below the current price of $105.63, occurring as the stock trades -18.7% from its 52-week high. Notably, Ligand reported a net loss of $-42,451,000.00 in its most recent quarter despite +27.3% annual revenue growth, indicating operational stress despite topline expansion. The CFO's same-ticker trading history at LGND shows 4 prior measurable sell transactions (2024–2025) with a 0 of 4 well-timed rate at the 90-day mark, meaning all prior sales were followed by positive returns—the stock rose after each sale, suggesting poor exit timing historically. This buy transaction occurs in that context of prior poorly-timed sells at the same company.

CFO Espinoza sells 5,000 LGND shares at $115.03; holds 26.4K post-transaction as stock declines -7.1% in 90 days

Espinoza sold 5,000 shares (-15.9% of his pre-transaction holdings) at $115.03 on 2025-03-04, reducing his stake to 26.4K shares. The stock has since declined 7.1% over the prior 90 days and trades 10.7% below its 52-week high of $129.90. His prior four sales at LGND all registered positive 90-day returns averaging +19.0%, indicating he historically sold before rallies rather than declines at this ticker. The company reported $51.8M quarterly revenue with +27.3% annual growth but remains unprofitable at -$7.2M net income on a full-year basis. This sale represents the continuation of a selling pattern at LGND but occurs in a context of recent stock weakness, departing from his prior execution timing at the company.